Curcumin potentiates antitumor activity of L-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1376-1382

  Wang, Hua ^a   Geng, Qi Rong ^a   Wang, Liang ^a   Lu, Yue ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

acute lymphoblastic leukemia; AKT; Curcumin; L asparaginase

Indexed keywords

ASPARAGINASE; CASPASE 3; CASPASE 8; CASPASE 9; CURCUMIN; CYTOCHROME C; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BID; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARAGINASE; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; JURKAT CELLS; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84861519400     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.649478     Document Type: Article

References (38)

1. Rowe JM, Buck G, Burnett AK, et al. XII/ECOG E2993 of more than 1500 patients from the international ALL trial: MRC UKALL induction therapy for adults with acute lymphoblastic leukemia: results. Blood 2005;106:3760-3767. (Pubitemid 41739010)
2. Gaynon PS. Childhood acute lymphoblastic leukemia and relapse. Br J Haematol 2005;131:579-587. (Pubitemid 43903802)
3. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer 2006;47:141-146. (Pubitemid 44025245)
4. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukemia cells. Biochem J 2001;357:321-328. (Pubitemid 32642933)
5. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113. (Pubitemid 28390409)
6. Asselin BL, Kreissman S, Coppola DJ, et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21:6-12. (Pubitemid 29131987)
7. Fine BM, Kaspers GJ, Ho M, et al. Genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-299. (Pubitemid 40070821)
8. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-2729.
9. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 2006;441:424-430. (Pubitemid 44050136)
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
11. Silva A, Yunes JA, Cardoso BA, et al. PTEN posttranslational inactivation and hyperactivation of the PI3-K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008;118:3762-3774.
12. Jiang R, Gu LB, Findley H, et al. Loss of PTEN expression induces NF-κB via PI3K/Akt pathway involving resistance to chemotherapy in acute lymphoblastic leukemia cell lines. Proc Am Assoc Cancer Res 2004;45: Abstract 1277.
13. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241. (Pubitemid 27456390)
14. Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789. (Pubitemid 26004411)
15. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321. (Pubitemid 28524494)
16. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868. (Pubitemid 29165088)
17. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in antiapoptotic PDGF signaling. Nature 1999;401:86-90.
18. Zhou MX, Gu LB, Zhu NG, et al. Transfection of a dominant-negative mutant NF-κB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene. 2003;22:8137-8144.
19. Gu LB, Findley HW, Zhou MX. MDM2 induces NF-κB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood 2002;99:3367-3375. (Pubitemid 34525318)
20. Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006;11:245-254. (Pubitemid 43291024)
21. Wang GB, Chen XQ, Geng QR, et al. Arsenic trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of β1-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma 2010;51:1090-1097.
22. Chen S, Chen Y, Hu C, et al. Association of clinicopathological features with UbcH10 expression in colorectal cancer. J Cancer Res Clin Oncol 2010;136:419-426.
23. Dai T-JQ. Quantitative analysis of combination therapy. Chin Pharmacol Bull 1998;14:479.
24. Yang Y, Lv QJ, Du QY, et al. Combined effects of cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol 2005;11:2491-2496. (Pubitemid 40667988)
25. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-6854. (Pubitemid 39383033)
26. Huang MT, Lou YR, Xie JG, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenzanthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998;19:1697-1700. (Pubitemid 28441876)
27. Huang MT, Ma W, Yen P, et al. Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 1997;18:83-88. (Pubitemid 28134619)
28. Li L, Aggarwal BB, Shishodia S, et al. Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-2362. (Pubitemid 39458693)
29. Mehta K, Pantazis P, McQueen T, et al. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines Anticancer Drugs 1997;8:470-481. (Pubitemid 27310917)
30. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007;30:905-918.
31. Watson JL, Greenshields A, Hill R, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. Mol Carcinog 2010;49:13-24.
32. Sikora E, Bielak-Zmijewska A, Magalska A, et al. Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. Mol Cancer Ther 2006;5:927-934. (Pubitemid 43724592)
33. Liu HL, Chen Y, Cui GH, et al. Curcumin, a potent antitumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin 2005;26:603-609. (Pubitemid 40676173)
34. Lodha R, Bagga A. Traditional Indian systems of medicine. Ann Acad Med Singapore 2000;29:37-41. (Pubitemid 30252144)
35. Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther 2004;3:1101-1108. (Pubitemid 39295007)
36. Kennedy SG, Kandel ES, Cross TK, et al. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 1999;19:5800-5810. (Pubitemid 29339934)
37. Henshall DC, Araki T, Schindler CK, et al. Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J Neurosci 2002;22:8458-8465. (Pubitemid 35387586)
38. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 2007;67:3853-3861. (Pubitemid 46762173)